Evaluation of monoclonal gammopathies

Last reviewed: 3 Sep 2022
Last updated: 31 Mar 2022

Summary

Differentials

Common

  • Monoclonal gammopathy of undetermined significance
  • Chronic lymphocytic leukemia
  • Non-Hodgkin lymphoma
Full details

Uncommon

  • Light chain deposition disease
  • Post-transplant monoclonal gammopathies
  • Multiple myeloma
  • Plasma cell leukemia
  • Waldenstrom macroglobulinemia
  • Solitary plasmacytoma
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes)
  • Hepatitis C
  • HIV infection
  • Primary amyloidosis
  • Cryoglobulinemia
  • Systemic lupus erythematosus (SLE)
  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Sjogren syndrome
  • Schnitzler syndrome
Full details

Contributors

Authors

Shaji Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies

Division of Hematology

Mayo Clinic

Rochester

MN

Disclosures

SK has received research funding for clinical trials for his institution from: Abbvie, Amgen, BMS, Carsgen, Janssen, KITE, Merck, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, and Tenebio. SK has participated in consulting and advisory boards (with no personal payment) for Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, KITE, Astra-Zeneca, Bluebird Bio, and (with personal payment) Oncopeptides, Beigene, and Antengene.

Peer reviewers

Antonio Palumbo, MD

Associate Professor

University of Turin

Chief

Myeloma Unit

Ospedale Molinette

Turin

Italy

Disclosures

AP declares that he has no competing interests.

John R. Wingard, MD

Price Eminent Scholar and Professor of Medicine Director

Bone Marrow Transplant Program

Division of Hematology and Oncology

University of Florida College of Medicine

Gainesville

FL

Disclosures

JRW declares that he has no competing interests.

John Densmore, MD, PhD

Associate Professor of Clinical Medicine

Department of Medicine

Division of Hematology/Oncology

University of Virginia

Charlottesville

VA

Disclosures

JD declares that he has no competing interests.

Use of this content is subject to our disclaimer